Skip to search formSkip to main contentSkip to account menu

motapizone

Known as: 4,5-dihydro-6-(4-(1H-imidazol-1-yl)-2-thienyl)-5-methyl-3(2H)-pyridazinone 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pyridazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Inhibition of thrombocyte aggregation by oral motapizone and other drugs
SummaryTen healthy subjects took single oral doses of placebo, 8.8±1.8 mg motapizone, 40±13 mg captopril, 25 mg dihydralazine, 20… 
2004
2004
Hypotensive and antiplatelet actions of motapizone depend on dose and time after ingestion
SummarySingle doses of motapizone 1 to 10 mg were given to 12 healthy subjects. Before and up to 8 h after each dose the blood… 
1995
1995
Activation of adenylate cyclase and phosphodiesterase inhibition enhance neutral endopeptidase activity in human endothelial cells
1995
1995
[Inhibition of histamine liberation in allergic rhinoconjunctivitis in relation to the season].
An increased activity of the cAMP-degrading enzyme phosphodiesterase (PDE) has been observed in peripheral leukocytes from atopic… 
1989
1989
[Mechanisms of thrombin-induced plasminogen activator release].
The protein kinase C inhibitor H7 (10(-5) mol/l) is able to inhibit the thrombin-induced t-PA release in the isolated perfused… 
1986
1986
Inhibition of human platelet aggregation by motapizone via an increase in intracellular cAMP.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)